Pipeline: New therapies to come for debilitating eye diseases

November 12, 2020
Gretchyn M. Bailey, NCLC, FAAO, Editor in Chief, Content Channel Director

,
Bernard Gilly, PhD

CEO, Gensight Biologics

New drug from Gensight Biologics hits pipeline

GenSight Biologics has developed a therapy for Leber hereditary optic neuropathy (LHON), called Lumevoq. The drug has been submitted for approval in Europe, and the company plans to submit for U.S. Food & Drug Administration approval in late 2021.

Dr. Gilly explains the mechanism of action for Lumevoq and provides a look into the GenSight Biologics pipeline for the future.

Related: Myopia control data and whats to come with Dr. Noel Brennan